Do We Need to Optimize Protein Binding in Drug Discovery?€¦ · Considerations of protein binding...
Transcript of Do We Need to Optimize Protein Binding in Drug Discovery?€¦ · Considerations of protein binding...
![Page 1: Do We Need to Optimize Protein Binding in Drug Discovery?€¦ · Considerations of protein binding in drug discovery • No need to specifically optimize plasma binding – Reduction](https://reader033.fdocuments.in/reader033/viewer/2022052723/5f0f00c47e708231d4420136/html5/thumbnails/1.jpg)
Do We Need to Optimize Protein Binding in Drug Discovery?
NEDMDG Summary Meeting June 4, 2013
Xingrong Liu, Ph.D.
Genentech
![Page 2: Do We Need to Optimize Protein Binding in Drug Discovery?€¦ · Considerations of protein binding in drug discovery • No need to specifically optimize plasma binding – Reduction](https://reader033.fdocuments.in/reader033/viewer/2022052723/5f0f00c47e708231d4420136/html5/thumbnails/2.jpg)
Free drug interacts with drug targets: Plasma
Total IC50 = 0.3- 300x Ki Free IC50 = 0.1-10x Ki
Liu et al., Drug Metab Dispos 37:1548–1556, 2009
![Page 3: Do We Need to Optimize Protein Binding in Drug Discovery?€¦ · Considerations of protein binding in drug discovery • No need to specifically optimize plasma binding – Reduction](https://reader033.fdocuments.in/reader033/viewer/2022052723/5f0f00c47e708231d4420136/html5/thumbnails/3.jpg)
Brain binding does not contribute to the activity: free drug interacts with drug targets
-20
0
20
40
60
80
100
0.01 0.1 1 10 100 1000 10000
Unbound Brain Concentration/KI
SE
RT
Occ
(%)
-20
0
20
40
60
80
100
0.01 0.1 1 10 100 1000 10000
Total Brain Concentration/KI
SE
RT
Occ
(%)
Total IC50 = 1-1000x Ki Free IC50 = 0.3-3x Ki
Liu et al., Drug Metab Dispos 37:1548–1556, 2009
![Page 4: Do We Need to Optimize Protein Binding in Drug Discovery?€¦ · Considerations of protein binding in drug discovery • No need to specifically optimize plasma binding – Reduction](https://reader033.fdocuments.in/reader033/viewer/2022052723/5f0f00c47e708231d4420136/html5/thumbnails/4.jpg)
Different effects of protein binding on in vitro and in vivo free concentrations
Cu ↑
Cbound
Cu
fu=0.1 Cbound
fu=0.5 fu=0.1 fu=0.5
Cu ↑
fu=0.5
Cu
fu ↑ Clin↓
fu ↑ Clin↔
Cbound
Cu↔ Cbound
Scenario 1
Scenario 2
In vitro In vivo
fu ↑
![Page 5: Do We Need to Optimize Protein Binding in Drug Discovery?€¦ · Considerations of protein binding in drug discovery • No need to specifically optimize plasma binding – Reduction](https://reader033.fdocuments.in/reader033/viewer/2022052723/5f0f00c47e708231d4420136/html5/thumbnails/5.jpg)
0.001
0.01
0.1
1
10
0 6 12 18 24Time (h)
Tota
l Con
c. (u
g/m
L)
G-378895 IV 3 mg/kg
G-378242 IV 3 mg/kg
0.0001
0.001
0.01
0.1
1
0 6 12 18 24Time (h)
Unb
ound
Con
c. (u
g/m
L)
G-378895 IV 3 mg/kg
G-378242 IV 3 mg/kg
Increase of free fraction by 15X increases IV free AUC by 3X
• 3X increase was due to reduced clearance
fup=0.15
fup=0.01 R1
R2
Cl
NR1
R2
![Page 6: Do We Need to Optimize Protein Binding in Drug Discovery?€¦ · Considerations of protein binding in drug discovery • No need to specifically optimize plasma binding – Reduction](https://reader033.fdocuments.in/reader033/viewer/2022052723/5f0f00c47e708231d4420136/html5/thumbnails/6.jpg)
0.01
0.1
1
10
0 6 12 18 24Time (h)
Tota
l Con
c. (u
g/m
L)
G-378895 PO 10 mg/kg
G-378242 PO 10 mg/kg
0.001
0.01
0.1
1
0 6 12 18 24Time (h)
Unb
ound
Con
c. (u
g/m
L)
G-378895 PO 10 mg/kg
G-378242 PO 10 mg/kg
Increase of free fraction by 15X increases oral free AUC 2X
• 2X increase was due to reduced clearance
fup=0.01
fup=0.15
R1
R2
Cl
NR1
R2
![Page 7: Do We Need to Optimize Protein Binding in Drug Discovery?€¦ · Considerations of protein binding in drug discovery • No need to specifically optimize plasma binding – Reduction](https://reader033.fdocuments.in/reader033/viewer/2022052723/5f0f00c47e708231d4420136/html5/thumbnails/7.jpg)
Protein binding vs. intrinsic clearance
Data form Blakey et al., J Pharmacokinet Biopharm 25:277–312, 1997
HN
HN
OO
R
C2H5
O
R = -(CH2)nCH3 n = 0-8
![Page 8: Do We Need to Optimize Protein Binding in Drug Discovery?€¦ · Considerations of protein binding in drug discovery • No need to specifically optimize plasma binding – Reduction](https://reader033.fdocuments.in/reader033/viewer/2022052723/5f0f00c47e708231d4420136/html5/thumbnails/8.jpg)
Protein binding vs. Vdss
Data form Blakey et al., J Pharmacokinet Biopharm 25:277–312, 1997
HN
HN
OO
R
C2H5
O
R = -(CH2)nCH3 n = 0-8
⎟⎟⎠
⎞⎜⎜⎝
⎛+=
tissue
plasma
fufu
VtVcVd
![Page 9: Do We Need to Optimize Protein Binding in Drug Discovery?€¦ · Considerations of protein binding in drug discovery • No need to specifically optimize plasma binding – Reduction](https://reader033.fdocuments.in/reader033/viewer/2022052723/5f0f00c47e708231d4420136/html5/thumbnails/9.jpg)
Protein binding vs. t1/2
Data form Blakey et al., J Pharmacokinet Biopharm 25:277–312, 1997
HN
HN
OO
R
C2H5
O
R = -(CH2)nCH3 n = 0-8
![Page 10: Do We Need to Optimize Protein Binding in Drug Discovery?€¦ · Considerations of protein binding in drug discovery • No need to specifically optimize plasma binding – Reduction](https://reader033.fdocuments.in/reader033/viewer/2022052723/5f0f00c47e708231d4420136/html5/thumbnails/10.jpg)
Protein binding vs. intrinsic clearance
Data form Obach et al., Drug Metab Dispos 36:1385–1405, 2008
0.1
1
10
100
1000
10000
100000
0.0001 0.001 0.01 0.1 1fu
Clin
(ml/m
in/k
g)
Acids
0.1
1
10
100
1000
10000
100000
0.0001 0.001 0.01 0.1 1fu
Clin
(ml/m
in/k
g)
Bases
0.1
1
10
100
1000
10000
100000
0.001 0.01 0.1 1fu
Clin
(ml/m
in/k
g)
Neutrals
1
10
100
1000
0.01 0.1 1fu
Clin
(ml/m
in/k
g)
Zwitterions
![Page 11: Do We Need to Optimize Protein Binding in Drug Discovery?€¦ · Considerations of protein binding in drug discovery • No need to specifically optimize plasma binding – Reduction](https://reader033.fdocuments.in/reader033/viewer/2022052723/5f0f00c47e708231d4420136/html5/thumbnails/11.jpg)
Protein binding vs. Vdss
Data form Obach et al., Drug Metab Dispos 36:1385–1405, 2008
⎟⎟⎠
⎞⎜⎜⎝
⎛+=
tissue
plasma
fufu
VtVcVd
![Page 12: Do We Need to Optimize Protein Binding in Drug Discovery?€¦ · Considerations of protein binding in drug discovery • No need to specifically optimize plasma binding – Reduction](https://reader033.fdocuments.in/reader033/viewer/2022052723/5f0f00c47e708231d4420136/html5/thumbnails/12.jpg)
Protein binding not associate with t1/2
0.1
1
10
100
1000
10000
0.0001 0.001 0.01 0.1 1fu
t1/2
(hr)
Acids
0.01
0.1
1
10
100
1000
0.0001 0.001 0.01 0.1 1fu
t1/2
(hr)
Bases
0.1
1
10
100
1000
0.001 0.01 0.1 1fu
t1/2
(hr)
Neutrals
0.1
1
10
100
0.01 0.1 1fu
t1/2
(hr)
Zwitterions
Data form Obach et al., Drug Metab Dispos 36:1385–1405, 2008
![Page 13: Do We Need to Optimize Protein Binding in Drug Discovery?€¦ · Considerations of protein binding in drug discovery • No need to specifically optimize plasma binding – Reduction](https://reader033.fdocuments.in/reader033/viewer/2022052723/5f0f00c47e708231d4420136/html5/thumbnails/13.jpg)
Brain unbound conc. is governed by the BBB and plasma unbound conc.
plasmauefflux
brainu C
PSClC ,,
1
1•
+=
Clefflux: efflux transport activity at the BBB PS: diffusion permeability at the BBB
![Page 14: Do We Need to Optimize Protein Binding in Drug Discovery?€¦ · Considerations of protein binding in drug discovery • No need to specifically optimize plasma binding – Reduction](https://reader033.fdocuments.in/reader033/viewer/2022052723/5f0f00c47e708231d4420136/html5/thumbnails/14.jpg)
Protein binding does not associate with brain penetration
Modified from Maurer et al, Drug Metab Dispos 33: 165, 2005
R2=0.077 R2=0.087
![Page 15: Do We Need to Optimize Protein Binding in Drug Discovery?€¦ · Considerations of protein binding in drug discovery • No need to specifically optimize plasma binding – Reduction](https://reader033.fdocuments.in/reader033/viewer/2022052723/5f0f00c47e708231d4420136/html5/thumbnails/15.jpg)
Significant effects of P-gp on brain concentration
Chen et al, Curr Drug Metab, 4: 272, 2003
8
14
14-27
16-28
18 CsA
Digoxin
Ivermectin Verapamil
Desloratadine
Compound Efflux Compound Efflux
![Page 16: Do We Need to Optimize Protein Binding in Drug Discovery?€¦ · Considerations of protein binding in drug discovery • No need to specifically optimize plasma binding – Reduction](https://reader033.fdocuments.in/reader033/viewer/2022052723/5f0f00c47e708231d4420136/html5/thumbnails/16.jpg)
Considerations of protein binding in drug discovery
• No need to specifically optimize plasma binding – Reduction of plasma protein binding alone does not increase free drug
concentration – Reduction of clearance increases free drug concentration – Reduction of plasma protein binding tends to associated with reduction
of clearance, as both of the parameters are governed by lipophilicity
• No need to specifically optimize brain binding • Reduction of brain tissue binding alone does not increase free brain drug
concentration • Reduction of efflux activity enhance free brain drug concentration
• Need to consider protein binding in … – PK/PD, human PK/dose/DDI prediction, drug transporter/tissue
penetration, safety margin calculation, regulatory filing, etc.
![Page 17: Do We Need to Optimize Protein Binding in Drug Discovery?€¦ · Considerations of protein binding in drug discovery • No need to specifically optimize plasma binding – Reduction](https://reader033.fdocuments.in/reader033/viewer/2022052723/5f0f00c47e708231d4420136/html5/thumbnails/17.jpg)
Acknowledgements
• Marcel Hop
• Bruce Roth • Joe Lyssikatos • R. Scott Obach • Franco Lombardo • Nigel J. Waters
• Dennis A. Smith
![Page 18: Do We Need to Optimize Protein Binding in Drug Discovery?€¦ · Considerations of protein binding in drug discovery • No need to specifically optimize plasma binding – Reduction](https://reader033.fdocuments.in/reader033/viewer/2022052723/5f0f00c47e708231d4420136/html5/thumbnails/18.jpg)
0%
5%
10%
15%
20%
25%
30%
<0.001 0.001-0.01 0.01-0.05 0.05-0.1 0.1-0.3 0.3-0.6 0.6-1
Unbound Fraction
Dru
gs (%
)
Protein binding of marketed drugs
Data from Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 11th
n = 267
n=14, fu<0.1
![Page 19: Do We Need to Optimize Protein Binding in Drug Discovery?€¦ · Considerations of protein binding in drug discovery • No need to specifically optimize plasma binding – Reduction](https://reader033.fdocuments.in/reader033/viewer/2022052723/5f0f00c47e708231d4420136/html5/thumbnails/19.jpg)
Many successful CNS drugs show high brain binding
0.0001
0.001
0.01
0.1
1
Sertr
alin
e
Chl
orpr
omaz
ine
Fluo
xetin
e
Paro
xetin
e
Nor
tript
ylin
ea
Hal
oper
idol
Cyc
lobe
nzap
rine
Fluv
oxam
ine
Clo
zapi
ne
Hyd
roxy
zine
Mid
azol
am
Cita
lopr
am
Prop
oxyp
hene
Traz
odon
e
Dia
zepa
m
Sele
gilin
e
Ris
perid
one
Phen
ytoi
n
9-O
H-R
ispe
ridon
e
Car
bam
azep
ine
Thio
pent
alc
Zolp
idem
a
Car
isop
rodo
l
Venl
afax
inec
Busp
irone
Lam
otrig
ine
Met
hylp
heni
date
Met
oclo
pera
mid
e
Mor
phin
e
Caf
fein
e
Hyd
roco
done
Sulp
iride
Mep
roba
mat
e
Bra
in fu
Modified from Maurer et al, Drug Metab Dispos 33: 165, 2005
![Page 20: Do We Need to Optimize Protein Binding in Drug Discovery?€¦ · Considerations of protein binding in drug discovery • No need to specifically optimize plasma binding – Reduction](https://reader033.fdocuments.in/reader033/viewer/2022052723/5f0f00c47e708231d4420136/html5/thumbnails/20.jpg)
0
5
10
15
20
25
thiop
ental
phen
ytoin
sulpi
ride
zolpi
dem
morphin
e
trazo
done
rispe
ridon
e
lamotrigi
ne
metoclo
peram
ide
busp
irone
hydro
codo
ne
propo
xyph
ene
parox
etine
seleg
iline
cloza
pine
venla
faxine
citalo
pram
fluvo
xamine
hydro
xyzin
e
nortr
iptyli
ne
cyclo
benz
aprin
e
fluox
etine
methylp
henid
ate
halop
erido
l
chlor
promaz
ine
sertra
line
midazo
lam
caris
oprod
ol
carba
mazepin
e
caffe
ine
ethos
uxim
ide
diaze
pam
AU
Cbr
ain/
AU
Cpl
asm
a (0
-5h)
0
5
10
15
20
25
thiop
ental
phen
ytoin
sulpi
ride
zolpi
dem
morphin
e
trazo
done
rispe
ridon
e
lamotrigi
ne
metoclo
peram
ide
busp
irone
hydro
codo
ne
propo
xyph
ene
parox
etine
seleg
iline
cloza
pine
venla
faxine
citalo
pram
fluvo
xamine
hydro
xyzin
e
nortr
iptyli
ne
cyclo
benz
aprin
e
fluox
etine
methylp
henid
ate
halop
erido
l
chlor
promaz
ine
sertra
line
midazo
lam
caris
oprod
ol
carba
mazepin
e
caffe
ine
diaze
pam
AU
Cu,
brai
n/A
UC
u,pl
asm
a (0-
5h)
Plasma and brain binding has a significant impact on the B/P ratio
Total Brain/Plasma Ratio
Unbound Brain/Plasma Ratio
Acid: 0.5 (0.4-0.6) Base: 6 ± 7 (0.1-24) Neutral: 0.9 ± 0.7 (0.2-0.8)
Acid: 0.2 (0.2-0.3) Base: 1 ± 0.7 (0.1-3.4) Neutral: 0.5 ± 0.3 (0.1-1)
Modified from Maurer et al, Drug Metab Dispos 33: 165, 2005
240x
34x
![Page 21: Do We Need to Optimize Protein Binding in Drug Discovery?€¦ · Considerations of protein binding in drug discovery • No need to specifically optimize plasma binding – Reduction](https://reader033.fdocuments.in/reader033/viewer/2022052723/5f0f00c47e708231d4420136/html5/thumbnails/21.jpg)
Protein binding vs. clearance
Data form Obach et al., Drug Metab Dispos 36:1385–1405, 2008
![Page 22: Do We Need to Optimize Protein Binding in Drug Discovery?€¦ · Considerations of protein binding in drug discovery • No need to specifically optimize plasma binding – Reduction](https://reader033.fdocuments.in/reader033/viewer/2022052723/5f0f00c47e708231d4420136/html5/thumbnails/22.jpg)
Protein binding vs. free Vdss
Data form Obach et al., Drug Metab Dispos 36:1385–1405, 2008
![Page 23: Do We Need to Optimize Protein Binding in Drug Discovery?€¦ · Considerations of protein binding in drug discovery • No need to specifically optimize plasma binding – Reduction](https://reader033.fdocuments.in/reader033/viewer/2022052723/5f0f00c47e708231d4420136/html5/thumbnails/23.jpg)
Questions for protein binding • PPB non-linearity – saturation of PPB as a strategy to increase
unbound concentration – is this a viable strategy? • Covalent modifiers – does PPB even matter? Is it always total
plasma concentration? • What about "exceptions to the rule"? - e.g. Active transport? Non-
well stirred assumption? • Impact on Cmax and Cmin – this could be sensitive to fu – see
Derendorf paper I circulated • Determination of unbound PK parameters (Clunbound –
Vd,ssunbound) – does this simplify or complicate things? • Species differences? • What should we use PPB data for in drug discovery?